Gross Profit
Breakdown
Segments
Tyvaso DPIView metric
Nebulized TyvasoView metric
RemodulinView metric
OrenitramView metric
UnituxinView metric
AdcircaView metric
OtherView metric
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Tyvaso DPI | $220.7M | $235.5M | $234.8M | $254.4M | $266.7M | $280.9M | $279.9M | $247.1M |
| Orenitram | $101.2M | $105.6M | $102.1M | $112.4M | $117.2M | $124.3M | $114.3M | $128.2M |
| Nebulized Tyvaso | $131.5M | $149.8M | $135.3M | $155.3M | $148.8M | $135.1M | $119.3M | $118.6M |
| Remodulin | $134.5M | $115M | $121.1M | $124.4M | $120.4M | $112.8M | $119.9M | $110.5M |
| Unituxin | $47.9M | $56.3M | $65.3M | $53M | $55.6M | $44.3M | $56.4M | $48.6M |
| Adcirca | $3.1M | $3.9M | $2.9M | $3.4M | $3.8M | $5.3M | $4.4M | $1.9M |
| Total | $637.1M | $665.8M | $660M | $701.9M | $711M | $698.6M | $686.8M | $648.1M |